R-Tech Ueno, Ltd. - Product Pipeline Review - Q4 2010

Global Markets Direct, November 2010, Pages: 32

R-Tech Ueno, Ltd. – Product Pipeline Review – Q4 2010

Summary

Global Market Direct’s pharmaceuticals report, “R-Tech Ueno, Ltd. - Product Pipeline Review - Q4 2010” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- R-Tech Ueno, Ltd. - Brief company overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of R-Tech Ueno, Ltd. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of R-Tech Ueno, Ltd. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the R-Tech Ueno, Ltd.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate R-Tech Ueno, Ltd.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of R-Tech Ueno, Ltd. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the R-Tech Ueno, Ltd.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with R-Tech Ueno, Ltd..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of R-Tech Ueno, Ltd. and identify potential opportunities in those areas.

List of Tables
List of Figures
R-Tech Ueno, Ltd. Snapshot
R-Tech Ueno, Ltd. Overview
Key Information
Key Facts
R-Tech Ueno, Ltd. – Research and Development Overview
Key Therapeutic Areas
R-Tech Ueno, Ltd. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
R-Tech Ueno, Ltd. – Pipeline Products Glance
R-Tech Ueno, Ltd. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
R-Tech Ueno, Ltd.–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
R-Tech Ueno, Ltd. – Drug Profiles
Ocuseva
Product Description
Mechanism of Action
R&D Progress
RK-023
Product Description
Mechanism of Action
R&D Progress
RU-101
Product Description
Mechanism of Action
R&D Progress
RTU-007
Product Description
Mechanism of Action
R&D Progress
RTU-1096
Product Description
Mechanism of Action
R&D Progress
R-Tech Ueno, Ltd. – Pipeline Analysis
R-Tech Ueno, Ltd. – Pipeline Products by Therapeutic Class
R-Tech Ueno, Ltd. Pipeline Products By Target
R-Tech Ueno, Ltd. – Pipeline Products by Route of Administration
R-Tech Ueno, Ltd. – Pipeline Products by Molecule Type
R-Tech Ueno, Ltd. – Recent Pipeline Updates
R-Tech Ueno, Ltd. – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
Jul 15, 2010: R-Tech Ueno Completes Phase II Clinical Study On Ophthalmic Solution UF-021 For Retinitis Pigmentosa
Jun 03, 2010: R-Tech Ueno Completes Phase II Clinical Study Of UF-021 For Treatment Of Retinitis Pigmentosa
Jun 03, 2010: Notification Related To The Completion Of The Phase II Clinical Study Of UF-021 (Ocuseva) On Retinitis Pigmentosa
Jun 03, 2010: Notification Related To The Completion Of The Phase II Clinical Study Of UF-021 (Ocuseva) On Retinitis Pigmentosa
Apr 05, 2010: R-Tech Ueno Applies For Marketing Approval Of Latanoprost Eye Drops 0.005% In Japan
Apr 05, 2010: R-Tech Ueno Applies For Marketing Approval Of Latanoprost Eye Drops 0.005% In Japan
Financial Deals Landscape
R-Tech Ueno, Ltd., Deals Summary, 2004 to 2010
R-Tech Ueno, Ltd. Detailed Deal Summary
Asset Purchase
Santen Pharmaceutical Acquires Marketing Rights For RESCULA From R-Tech Ueno
Licensing Agreements
Mitsubishi Tanabe Enters Into License Agreement With R-Tech Ueno
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

Customers who bought this item also bought

• Sports and Fitness Nutrition - Global Strategic Business Report
• eLEARNING - Global Strategic Business Report
• Aerospace and Defense Industry - Global Strategic Business Report
• International Military and Civilian Unmanned Aerial Vehicle Survey
• Biodefense Industry - Market to Benefit from Federal Funding such as the BIO EDEP Fund to Support Security Plans
• Charter Schools - Global Outlook
• Education Services - Global Strategic Business Report
• Commercial And Military Flight Simulation - Global Strategic Business Report
• Defense Robotics - Global Strategic Business Report
• International Military and Government Helicopter Survey